Ann: Reinstatement to Official Quotation, page-33

TB2 you are right but I think it will help to get the market enthused if “something” was a little clearer and defined. I understood that “something” into clinical was a CPP capable of towing a DMD drug. That in itself would be great and would excite your first possibility re the platform. But, who knows what the path is? I’m only guessing. The market I am sure would like to embrace something with a name - DMD, cancer etc. The market would also like to understand timing - I hear excitement in the various posts but I also hear end of 2019 (which potentially coincides with next cash requirement). I’m not very excited about that. Is there something on a nearer horizon?